Objectives: Cognitive impairment is the main character of Alzheimer's disease (AD). This study mainly focused on whether mogrol, a tetracyclic triterpenoids compound of Siraitia grosvenorii Swingle, can ameliorate the memory impairment induced by Aβ1-42 .
Methods: Memory impairment mice model was made by stereotactic intra-hippocampal microinjection of Aβ1-42 (410 pm/mouse). Mogrol (20, 40, 80 mg/kg) was given to mice by intragastric administration at 3 days after Aβ1-42 injection for totally 3 weeks. Morris water maze test and Y-maze test were operated to evaluate the therapeutic effect of morgrol on Aβ1-42 -induced memory impairments. Immunohistochemical analyses and Hoechst 33258 assay were used to evaluate effect of morgrol on Aβ1-42 -induced microglia overactivation and apoptotic response in hippocampus of mice. Western blotting assay was used to evaluate effect of mogrol on the Aβ1-42 -activated NF-κB signaling.
Key findings: Mogrol could significantly alleviate Aβ1-42 -induced memory impairments, inhibit Aβ1-42 -induced microglia overactivation and prevent Aβ1-42 -triggered apoptotic response in the hippocampus. Mogrol also could suppress Aβ1-42 -activated NF-κB signaling, reduce the production of proinflammatory cytokines.
Conclusions: This study suggested that mogrol would ameliorate the memory impairment induced by Aβ1-42 , which is involved in anti-inflammation and anti-apoptosis in the brain.
Keywords: Alzheimer's disease; NF-κB; apoptosis; inflammation; mogrol.
© 2018 Royal Pharmaceutical Society.